AtomixRx Ltd.
Medical Devices — Stage: Seed. Est: 2025. Tags: Artificial Intelligence, Autoimmune Diseases, Life Sciences. AtomiX is developing first-in-class oral TNFα inhibitors, based on a newly discovered binding pocket, combining AI-driven design and human organoid models to deliver safer, more effective therapies for autoimmune and inflammatory diseases.. Web: